Timon Bogumil

1.6k total citations · 1 hit paper
21 papers, 1.2k citations indexed

About

Timon Bogumil is a scholar working on Pathology and Forensic Medicine, Rheumatology and Oncology. According to data from OpenAlex, Timon Bogumil has authored 21 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pathology and Forensic Medicine, 10 papers in Rheumatology and 7 papers in Oncology. Recurrent topics in Timon Bogumil's work include Multiple Sclerosis Research Studies (16 papers), Systemic Lupus Erythematosus Research (6 papers) and Immunotherapy and Immune Responses (4 papers). Timon Bogumil is often cited by papers focused on Multiple Sclerosis Research Studies (16 papers), Systemic Lupus Erythematosus Research (6 papers) and Immunotherapy and Immune Responses (4 papers). Timon Bogumil collaborates with scholars based in Germany, United States and Canada. Timon Bogumil's co-authors include Matteo Giuseppe Cereda, Carel B. Hoyng, Philip Hykin, Alan R. Berger, Rafael Cortez, Stephanie Heldner, Stephen Beatty, Theresa Heah, Giovanni Staurenghi and Sobha Sivaprasad and has published in prestigious journals such as Neurology, The Lancet Neurology and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

Timon Bogumil

21 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration

2014 464 citations Frank G. Holz, Ramin Tadayoni et al. British Journal of Ophthalmology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Timon Bogumil Germany	12	561	456	400	230	216	21	1.2k
H. Nida Sen United States	17	122 0.2×	760 1.7×	167 0.4×	137 0.6×	253 1.2×	40	1.3k
R. Phillip Kinkel United States	4	1.0k 1.8×	92 0.2×	46 0.1×	402 1.7×	574 2.7×	4	1.1k
Ruth van der Gaag Netherlands	15	349 0.6×	216 0.5×	219 0.5×	22 0.1×	90 0.4×	26	780
George E. Sanborn United States	21	119 0.2×	1.4k 3.1×	606 1.5×	59 0.3×	236 1.1×	56	1.8k
Pedro Oyuela United States	7	938 1.7×	29 0.1×	75 0.2×	286 1.2×	362 1.7×	16	1.2k
Don‐Il Ham South Korea	18	31 0.1×	750 1.6×	516 1.3×	122 0.5×	35 0.2×	56	997
M. Stojanovic Serbia	8	815 1.5×	15 0.0×	69 0.2×	249 1.1×	361 1.7×	18	1.0k
Irmgard Mayringer Austria	6	440 0.8×	12 0.0×	106 0.3×	174 0.8×	228 1.1×	7	634
Tamara Miller United States	6	799 1.4×	15 0.0×	62 0.2×	247 1.1×	319 1.5×	23	958
T. Pickersgill United Kingdom	8	582 1.0×	16 0.0×	58 0.1×	192 0.8×	253 1.2×	12	730

Countries citing papers authored by Timon Bogumil

Since Specialization

Citations

This map shows the geographic impact of Timon Bogumil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timon Bogumil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timon Bogumil more than expected).

Fields of papers citing papers by Timon Bogumil

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timon Bogumil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timon Bogumil. The network helps show where Timon Bogumil may publish in the future.

Co-authorship network of co-authors of Timon Bogumil

This figure shows the co-authorship network connecting the top 25 collaborators of Timon Bogumil. A scholar is included among the top collaborators of Timon Bogumil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timon Bogumil. Timon Bogumil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schippling, Sven, Paul O’Connor, Volker Knappertz, et al.. (2016). Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. Journal of Neurology. 263(7). 1418–1426. 38 indexed citations

Hartung, Hans-Peter, Ludwig Kappos, Douglas S. Goodin, et al.. (2015). Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. Journal of Neurology. 262(11). 2466–2471. 3 indexed citations

Holz, Frank G., Ramin Tadayoni, Stephen Beatty, et al.. (2014). Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. British Journal of Ophthalmology. 99(2). 220–226. 464 indexed citations breakdown →

Hartung, Hans, Lawrence Steinman, Douglas S. Goodin, et al.. (2013). Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis. JAMA Neurology. 70(8). 1017–1017. 28 indexed citations

Lampl, Christian, Stefan Nagl, Barry G.W. Arnason, et al.. (2013). Efficacy and safety of interferon beta-1b sc in older RRMS patients—a posthoc analysis of the BEYOND study. Journal of Neurology. 260(7). 1838–1845. 8 indexed citations

Hartung, Hans-Peter, Bernd C. Kieseier, Douglas S. Goodin, et al.. (2012). Variability in detection and quantification of interferon β-1b–induced neutralizing antibodies. Journal of Neuroinflammation. 9(1). 129–129. 6 indexed citations

Ebers, George C., Anthony Traboulsee, Dawn Langdon, et al.. (2010). Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. Journal of Neurology Neurosurgery & Psychiatry. 81(8). 907–912. 92 indexed citations

Reder, Anthony T., George C. Ebers, Anthony Traboulsee, et al.. (2010). Cross-sectional study assessing long-term safety of interferon-β-1b for relapsing-remitting MS. Neurology. 74(23). 1877–1885. 48 indexed citations

O’Connor, Paul, Massimo Filippi, Barry G.W. Arnason, et al.. (2009). 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. The Lancet Neurology. 8(10). 889–897. 295 indexed citations

10.

Arnason, B. G. W., et al.. (2009). PO10-TU-56 Depression incidence and course in multiple sclerosis patients treated with interferon beta-1b and glatiramer acetate during the BEYOND trial. Journal of the Neurological Sciences. 285. S211–S211. 1 indexed citations

11.

Dressel, Alexander, Dirk Bahner, Andreas Bitsch, et al.. (2008). MxA protein – an interferon beta biomarker in primary progressive multiple sclerosis patients. European Journal of Neurology. 15(8). 822–826. 5 indexed citations

12.

Dressel, Alexander, Andreas Bitsch, Timon Bogumil, et al.. (2006). Interferon-?1b treatment modulates cytokines in patients with primary progressive multiple sclerosis. Acta Neurologica Scandinavica. 114(6). 368–373. 6 indexed citations

13.

Polman, Chris H., Ludwig Kappos, Frank Dahlke, et al.. (2005). Interferon beta-1b treatment does not induce autoantibodies. Neurology. 64(6). 996–1000. 22 indexed citations

14.

Bitsch, Andreas, Alexander Dressel, Timon Bogumil, et al.. (2004). Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b. Journal of Neurology. 251(12). 1498–1501. 14 indexed citations

15.

Bitsch, Andreas, Dirk Bahner, Timon Bogumil, et al.. (2004). Interferon beta-1b modulates serum sVCAM-1 levels in primary progressive multiple sclerosis. Acta Neurologica Scandinavica. 110(6). 386–392. 5 indexed citations

16.

Bitsch, Andreas, Alexander Dressel, Hayrettin Tumani, et al.. (2003). Interferon-?-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis. Journal of Neurology. 250(10). 1224–1228. 40 indexed citations

17.

Bahner, Dirk, Bernd Kitze, Timon Bogumil, et al.. (2002). Interferon-beta-1b increases serum interleukin-12 p40 levels in primary progressive multiple sclerosis patients. Neuroscience Letters. 326(2). 125–128. 7 indexed citations

18.

Brettschneider, Johannes, D. Ecker, Andreas Bitsch, et al.. (2002). The macrophage activity marker sCD14 is increased in patients with multiple sclerosis and upregulated by interferon beta-1b. Journal of Neuroimmunology. 133(1-2). 193–197. 30 indexed citations

19.

Bogumil, Timon, Peter Rieckmann, Boris Kubuschok, K. Felgenhauer, & Wolfgang Brück. (1998). Serum levels of macrophage-derived protein MRP-8/14 are elevated in active multiple sclerosis. Neuroscience Letters. 247(2-3). 195–197. 38 indexed citations

20.

Kaaden, O.‐R., Uwe Truyen, Martin H. Groschup, et al.. (1994). Bovine Spongiform Encephalopathy in Germany. Journal of Veterinary Medicine Series B. 41(1-10). 294–304. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact